(Q34459832)

2 August 2017

1 reference

title

Trials within trials: confirmatory subgroup analyses in controlled clinical experiments (English)

1 reference

2 August 2017

Moyé LA

1

1 reference

2 August 2017

Deswal A

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

Contemporary Clinical Trials

2 August 2017

published in

1 reference

2 August 2017

volume

22

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

605-619

1 reference

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Large-scale randomized evidence: large, simple trials and overviews of trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Subgroup analysis and other (mis)uses of baseline data in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

1 reference

7 January 2021

Patient subsets and variation in therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

P-value interpretation and alpha allocation in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Alpha calculus in clinical trials: considerations and commentary for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Carvedilol in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Carvedilol and the Food and Drug Administration approval process: an introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

End-point interpretation in clinical trials: the case for discipline

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Within trial variation--a false trail?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

The problem of cogent subgroups: a clinicostatistical tragedy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

Empirical Bayes estimates of subgroup effects in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

A Bayesian approach to the interpretation of subgroup results in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2801%2900180-5

7 January 2021

10.1016/S0197-2456(01)00180-5

Identifiers

DOI

1 reference

2 August 2017

1 reference